Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Prostate cancer study tracks immune changes during brachytherapy

NCT ID NCT07131956

Knowledge-focused Sponsor: University of Erlangen-Nürnberg Medical School Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at how the immune system changes in men with prostate cancer who receive brachytherapy (internal radiation). Researchers will collect blood and tissue samples before, during, and after treatment to track immune cells and DNA. The goal is to better understand the body's response to radiation, not to test a new drug. About 200 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal how brachytherapy affects the immune system, potentially guiding future combination treatments for prostate cancer.
What could go wrong
This is an observational study, not a treatment trial. It will not directly improve outcomes for participants and may not lead to any new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Prostate cancer patients planning to undergo sole brachytherapy treatment

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Arm 1: * Primary treatment with I-125 seeds or HDR-BT * No previous treatment for prostate cancer * Age ≥ 18 years Inclusion Criteria Arm 2: * HDR- or PDR-BT * No radiation therapy within three months before salvage treatment * Complete documentation available on previous treatment for prostate cancer * No history of prostatectomy * Age ≥ 18 years Exclusion Criteria: * Pre-existent auto-immune disease * patients under bloodthinning medication * substance abuse

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer (diagnosis) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease hormone-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer (diagnosis) Prostate cancer patients treated by radiotherapy Prostate cancer patients who have brachytherapy seed implant Prostate cancer recurrent

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Klinik für Strahlentherapie

    NOT_YET_RECRUITING

    Augsburg, Bavaria, 86156, Germany

  • Klinik und Poliklinik für Strahlentherapie und Radioonkologie

    NOT_YET_RECRUITING

    Munich, Bavaria, 81377, Germany

  • Strahlenklinik Erlangen

    RECRUITING

    Erlangen, Bavaria, 91054, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.